Latest stories on CLLS
CLLS Stock Rallies Over 24% After Hours — Here's Why
Stocktwits News77 · bullishproduct/pr
Cellectis Gains FDA RMAT Status for Allogeneic CAR-T lasme-cel in r/r B-ALL
TipRanks77 · bullishproduct/pr
Cellectis Receives FDA RMAT Designation for lasme-cel, the First Allogeneic CAR-T Therapy in a Pivotal Trial for Patients with r/r B-ALL
Business Insider77 · bullishproduct/pr
Monthly information on share capital and company voting rights | CLLS Stock News
StockTitan50 · neutralgeneral